

Regimen Reference Order – SUPP – dexrazoxane

Planned Course: Refer to prescribed anthracycline-based protocol

Indication for Use: Cardioprotection for adult patients with a high lifetime cumulative anthracycline dose

dexrazoxane:

- *is prepared by Pharmacy*
- *has specific administration, stability and compounding considerations for Pharmacy and Nursing. Advance notice should be provided to Pharmacy*
- *must be administered prior to anthracycline to provide cardioprotection*

CVAD: Preferred (VESICANT INVOLVED)

Blood work requirements:

❖ *Refer to prescribed anthracycline-based protocol*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements		
Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed anthracycline-based protocol</i>		

Treatment Regimen – SUPP – dexrazoxane		
Establish primary solution 500 mL of: normal saline or D5W according to the prescribed anthracycline-based protocol Primary solution of Lactated Ringer’s is NOT required		
Drug	Dose	CCMB Administration Guideline
Pre-medications	Refer to prescribed anthracycline-based protocol	
dexrazoxane	*Dose as specified in protocol	IV made up to a final concentration of 3 mg/mL in Lactated Ringer’s over 30 minutes immediately prior to the administration of anthracycline <i>*Nursing Alert: dexrazoxane infusion must be complete prior to anthracycline administration</i>
Anthracycline	Refer to prescribed anthracycline-based protocol <i>*Nursing Alert: anthracycline must be administered within 30 minutes after completion of dexrazoxane infusion</i>	

Additional cancer therapy agents if applicable	Follow sequence prescribed in anthracycline-based protocol
* dexrazoxane dose (mg/m ²) is usually dosed at a ratio of dexrazoxane: DOXOrubicin 10:1. Refer to Shared health Parenteral Drug Monograph for further information	

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

REQUIRED MONITORING

All Cycles

- Serum creatinine and urea as per Physician Orders
- Refer to the prescribed anthracycline-based protocol for additional required monitoring

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
<i>Refer to prescribed anthracycline-based protocol</i>		

DISCHARGE INSTRUCTIONS

- Refer to the prescribed anthracycline-based protocol for additional discharge instructions
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- This protocol is intended for adult patients only
- dexrazoxane is prescribed to provide cardioprotection from anthracycline-associated cardiotoxicity. Anthracyclines include DOXOrubicin, epiRUBicin, DAUNOrubicin and IDArubicin
- Consideration is given to adding dexrazoxane if a patient is benefiting from anthracycline therapy, and cumulative lifetime doses are as follows:
 - DOXOrubicin greater than 300 mg/m² OR
 - epiRUBicin greater than 550 mg/m²
- Medical oncologist must write first prescription of dexrazoxane
- Refer to the prescribed anthracycline-based protocol for additional information
- Due to final stability of the compounded product, administration site restrictions may be in place for dexrazoxane